Quantcast

Latest Novartis Pharmaceuticals Corporation Stories

2014-10-15 16:30:25

- Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL0191 EAST HANOVER, N.J., Oct. 15, 2014 /PRNewswire/ -- Novartis and the University of Pennsylvania's Perelman School of Medicine (Penn) today announced preliminary results from two pilot clinical trials published in The New England Journal of Medicine (NEJM) evaluating the efficacy and safety of CTL019 in patients...

2014-09-27 08:21:23

- Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1) EAST HANOVER, N.J., Sept. 27, 2014 /PRNewswire/ -- Novartis today presented final results on overall survival (OS) from a Phase III trial of Afinitor(®) (everolimus) tablets plus best supportive care (BSC) compared to placebo plus BSC in patients with well-differentiated advanced and progressive pancreatic...

2014-09-23 23:06:16

Best of the Best in Healthcare Marketing Honored at Gala Event NEW YORK, NY (PRWEB) September 23, 2014 PM360, a leading health-marketing industry trade magazine, recognized the best innovators in the pharmaceutical industry with their annual Trailblazer Awards on Thursday, September 18, 2014. The honors, bestowed at a gala banquet at Gotham Hall in New York City, are given to outstanding companies, marketers and brand managers representing top talent and brands. “This industry...

2014-08-30 08:20:58

- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1) EAST HANOVER, N.J., Aug. 30, 2014 /PRNewswire/ -- Today at the European Society of Cardiology congress and published simultaneously in the New England Journal of Medicine, Novartis revealed that its investigational heart failure medicine, LCZ696, was superior to ACE-inhibitor enalapril on key endpoints in the largest heart failure study ever...

2014-08-11 00:20:49

-- LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF EAST HANOVER, N.J., Aug. 11, 2014 /PRNewswire/ -- New data revealing the reduction in cardiovascular (CV) deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction (HF-REF) will be presented at the world's largest cardiology congress, the European Society of Cardiology (ESC) Congress 2014, on Sunday...

2014-07-09 16:28:56

- Results of two Phase III psoriasis studies show secukinumab, the first psoriasis IL-17A inhibitor filed with regulatory bodies, met all co-primary and key secondary endpoints[1] EAST HANOVER, N.J., July 9, 2014 /PRNewswire/ -- Novartis today announced that The New England Journal of Medicine (NEJM) published the results from two pivotal Phase III studies evaluating the interleukin-17A (IL-17A) inhibitor secukinumab (AIN457). Secukinumab met all primary and key secondary...

2014-07-07 12:29:12

- Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) EAST HANOVER, N.J., July 7, 2014 /PRNewswire/ -- Novartis announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic...

2014-06-02 16:26:19

- Ceritinib achieved overall response rate of 58.5%, with a median progression-free survival of 8.2 months1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today announced data showing Zykadia((TM) )(ceritinib, previously known as LDK378) shrank tumors in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC), including those who had received previous treatment with an ALK inhibitor as well as patients receiving one for the first time. Results...

2014-06-02 08:32:06

Results show adding LBH589 to bortezomib and dexamethasone significantly improved PFS by 37%, meeting Phase III study primary endpoint1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial showing a 37% improvement in progression-free survival (PFS) when using the investigational compound LBH589 (panobinostat) in combination with bortezomib[*] and dexamethasone compared to treatment with the same regimen with placebo in patients with...

2014-06-01 08:20:47

The study met the primary endpoint with objective response rates of 41.8% and 32.5% respectively in the 200 mg and 800 mg treatment arms(1,2) EAST HANOVER, N.J., June 1, 2014 /PRNewswire/ -- Novartis announced today the results of a pivotal Phase II trial demonstrating that patients with locally advanced (laBCC) or metastatic basal cell carcinoma (mBCC) taking the investigational oral compound LDE225 (sonidegib) had marked and sustained tumor shrinkage after a median follow-up of...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related